Public Notices: Peak Powder River Resources, LLC (F031172/A0016113)
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
05/06/2024 | Press release | Distributed by Public on 05/06/2024 07:17
Please select the service you want to use:
Smartlinks | Loews Corporation | Finance | Security Markets | Security Markets | Company News | Securities Issuers | Investment Holding Companies | London Stock Exchange (LSE) | New York Stock Exchange (NYSE) | Frankfurt Stock Exchange | Sao Paulo Stock Exchange (B3) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Stuttgart Stock Exchange | Bolsa Mexicana de Valores (BMV) | BX Swiss | Tradegate Exchange | NYSE American | NYSE ARCA Equities | Cboe BZX Exchange | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | Investors Exchange (IEX) | Nasdaq BX | Nasdaq Intermarket | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact